Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,638 matching trials from the live ClinicalTrials.gov search.
Filters: Los Angeles, California Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309
View directory record Official record
Conditions
Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions
Not listed
Lead sponsor
Marinella Temprosa
Other
Eligibility
Not listed
Enrollment
1,976 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Recruiting Phase 3 Interventional

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Not applicable Interventional

Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease

NCT03301311
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Specific Carbohydrate Diet (SCD), Modified Specific Carbohydrate Diet (MSCD)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting No phase listed Observational

Long Term Follow up of Children Enrolled in the REDvent Study

NCT03709199
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Ventilator-Induced Lung Injury, Neurocognitive Dysfunction, Quality of Life, Respiration Disorders
Interventions
Ventilation Inhomogeneity, Diaphragm Ultrasound, Respiratory Inductance Plethysmography, Spirometry, Functional Residual Capacity, MIP/MEP, 6 minute walk test, Neurocognitive Testing, Emotional Health Assessment, Health Related Quality of Life, Functional Status, Respiratory Status Questionnaire
Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Month to 18 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

NCT03522298
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Paxalisib (GDC-0084)
Drug
Lead sponsor
Kazia Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Nov 5, 2026, 5:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Golf for Veterans Study

NCT04004598
View directory record Official record
Conditions
Exercise Training
Interventions
golf training
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

NCT00083304
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen
Drug · Radiation · Other
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Urinary Biomarkers of OI Pathobiology

NCT02531087
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Recruiting Phase 3 Interventional

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916
View directory record Official record
Conditions
Melanoma
Interventions
fianlimab, cemiplimab, relatlimab+nivolumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
106
States / cities
Chandler, Arizona • Gilbert, Arizona • Tucson, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Results available

Finding the Optimum Regimen for Duchenne Muscular Dystrophy

NCT01603407
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisone, Deflazacort
Drug
Lead sponsor
University of Rochester
Other
Eligibility
4 Years to 7 Years · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Nov 5, 2026, 5:03 PM EST
Completed Not applicable Interventional Results available

Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation

NCT00333619
View directory record Official record
Conditions
Sleep Disorders
Interventions
Nonpharmacological sleep intervention, Active control
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sepulveda, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Nov 5, 2026, 5:03 PM EST
Completed No phase listed Observational

Multicenter Perioperative Opioid Pharmacogenetic Study

NCT01495611
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)

NCT00608764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 80 Years
Enrollment
10,718 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

Vinblastine and Methotrexate in Treating Children With Desmoid Tumors

NCT00003019
View directory record Official record
Conditions
Desmoid Tumor
Interventions
methotrexate, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1 Interventional Results available

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Decitabine, Vorinostat, Filgrastim (G-CSF), Fludarabine, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Results available

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

NCT00868699
View directory record Official record
Conditions
Bipolar Depression
Interventions
lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
22
States / cities
Escondido, California • Garden Grove, California • Oceanside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

NCT00002941
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Nov 5, 2026, 5:03 PM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

NCT04680637
View directory record Official record
Conditions
Active Systemic Lupus Erythematosus
Interventions
Efavaleukin Alfa, Placebo, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
51
States / cities
Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Nov 5, 2026, 5:03 PM EST
Completed No phase listed Observational

Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)

NCT02224677
View directory record Official record
Conditions
Craniofacial Microsomia, Hemifacial Microsomia, Oculo-Auriculo-Vertebral-Syndrome, Goldenhar Syndrome, Microtia
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Months to 24 Months
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

NCT04349436
View directory record Official record
Conditions
Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Interventions
RP1, intra-tumoral injection, oncolytic virus
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536
View directory record Official record
Conditions
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Interventions
DB-OTO
Genetic
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

NCT00046319
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BSF 208075
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Nov 5, 2026, 5:03 PM EST